Bayer is likely to seek a major life sciences M&A deal in the next few years, according to banking sources, as its absence from a recent wave of consolidation could undermine its position in markets such as crop protection and animal health.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com